益气养阴汤联合化疗治疗上皮性卵巢癌的疗效分析  

Efficacy of Yiqi Yangyin Decoction Combined with Chemotherapy in the Treatment of Epithelial Ovarian Cancer

作　　者：张璐璐 沈秋娴 李安[3] 岑谋娟 孙晓峰[5] ZHANG Lulu;SHEN Qiuxian;LI An;CEN Moujuan;SUN Xiaofeng(Department of Traditional Chinese Medicine,Guangdong Maternal and Child Health Hospital,Guangzhou 510000 Guangdong,China;Department of Gynecology,Shunde Hospital,Guangzhou University of Chinese Medicine,Foshan 528000 Guangdong,China;Department of Gynecology,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510000 Guangdong,China;Guangzhou Kapok Pearl City Medical Clinic,Guangzhou 510000 Guangdong,China;Department of Obstetrics,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510000 Guangdong,China)

机构地区：[1]广东省妇幼保健院中医科,广东广州510000 [2]广州中医药大学顺德医院妇科,广东佛山528000 [3]广州中医药大学第一附属医院妇科,广东广州510000 [4]广州木棉花珠城医疗门诊部,广东广州510000 [5]广州中医药大学第一附属医院产科,广东广州510000

出　　处：《中医肿瘤学杂志》2025年第1期7-15,共9页Journal of Oncology in Chinese Medicine

基　　金：国家中医药管理局中医药科学技术研究专项课题(编号:2022ZX987);广东省中医药局科研项目(编号:20222051)。

摘　　要：目的基于重复测量方差分析观察益气养阴汤联合化疗治疗上皮性卵巢癌的临床疗效。方法选取2021年1月至2023年8月于广州中医药大学第一附属医院治疗的101位上皮性卵巢癌患者,随机分为研究组(52例)与对照组(49例),依据患者资料对两组进行倾向性评分匹配调整,匹配成功后两组患者各45例,共计90例。对照组采用TC(紫杉醇联合卡铂)化疗方案治疗,21天化疗一次,治疗6个月。研究组在对照组的基础上,连续服用益气养阴汤6个月。于治疗前、治疗1个月、治疗3个月与治疗6个月分别测量两组患者的肿瘤标志物水平及细胞免疫水平,并采用重复测量方差分析疗效;同时对比两组治疗前后肿瘤客观治疗效果、中医证候积分,综合评价两组对上皮性卵巢癌的治疗效果。通过Log-binomial回归分析两组不良反应发生情况。结果重复测量方差分析结果表明,两组患者的血清糖类抗原125(carbohydrate antigen 125,CA125)、人附睾上皮分泌蛋白4(human epididymis protein 4,HE4)、癌胚抗原(carcinoembryonic antigen,CEA)及CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)在时间效应、组间效应与交互效应上差异均具有统计学意义(P<0.05)。单独效应检验结果显示,研究组与对照组患者肿瘤标志物及细胞免疫水平随时间变化的趋势有所不同。治疗1个月后,两组间HE4水平无明显差异(P>0.05),CA125、CEA水平差异具有统计学意义(P<0.05)。从治疗3个月开始,研究组的CA125、HE4、CEA均显著低于对照组(P<0.05);两组患者CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)值均低于治疗前,且研究组各细胞免疫指标从治疗1个月开始均显著高于对照组(P<0.05)。治疗6个月后,研究组客观缓解率与疾病控制率分别为77.78%与93.33%,显著高于对照组(P<0.05);研究组中医证候积分为22.07±5.11,显著低于对照组。两组不良反应发生率分别为8.89%和26.67%,差异有统计学意义(P<0.05),与对照组相比,研究组Objective To observe of the clinical efficacy of Yiqi Yangyin Decoction combined with chemotherapy in the treatment of epithelial ovarian cancer based on repeated measures analysis of variance.Methods A total of 101 patients with epithelial ovarian cancer treated at the First Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2021 to August 2023 were randomly divided into a study group(52 cases)and a control group(49 cases).The two groups were adjusted for propensity score matching based on patient data.After successful matching,there were 45 patients in each group,for a total of 90 patients.The control group was treated with TC(paclitaxel combined with carboplatin)chemotherapy regimen,once every 21 days for six months.The study group received continuous treatment with Yiqi Yangyin Decoction for six months in addition to the treatment of the control group.The levels of tumor markers and cellular immunity in the two groups of patients were measured before treatment,one month after treatment,three months after treatment,and six months after treatment,and repeated measures analysis of variance was used to evaluate the efficacy.Simultaneously,the objective therapeutic effect and traditional Chinese medicine(TCM)syndrome score of the two groups were compared before and after treatment,and the therapeutic effect of the two groups on epithelial ovarian cancer were comprehensively evaluated.The occurrence of adverse reactions in the two groups was analyzed through Log-binomial regression analysis.Results The results of repeated measures analysis of variance showed that there were statistically significant differences in carbohydrate antigen 125(CA125),human epididymitis protein 4(HE4),carcinoembryonic antigen(CEA),CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)between the two groups of patients in terms of time effect,inter group effect,and interaction effect(P<0.05).The results of the individual effect test showed that there were differences in the trends of tumor marker levels and cellular immune levels o

关 键 词：益气养阴汤 上皮性卵巢癌 重复测量方差分析 肿瘤标志物 细胞免疫 

分 类 号：R273[医药卫生—中西医结合] R737.31[医药卫生—中医肿瘤科]